Costigan D C, Holland F J, Daneman D, Hesslein P S, Vogel M, Ellis G
Pediatrics. 1986 May;77(5):703-8.
Thyroid function was systematically evaluated in 15 consecutive children (mean age 13.7 years, range 0.5 to 19.5 years) before and serially during treatment with amiodarone (Cordarone), a potent antiarrhythmic agent. Amiodarone is known to affect thyroid homeostasis by competitive inhibition of 5'-monodeiodinase, which converts L-thyroxine (T4) to triiodothyronine (T3) and reverse T3 (rT3) to 3,3'-diodothyronine (T2), and also by the direct effects of its high iodine content (37% by weight). Clinical and/or biochemical evidence of hypothyroidism occurred in three patients, two of whom required treatment with L-thyroxine. An additional patient had persistent hyperthyroxinemia but no clinical evidence of hyperthyroidism. Results from the patients who remained euthyroid showed characteristic alterations in serum thyroid function tests. These included significant increases in serum T4, rT3, basal thyroid-stimulating hormone and thyroid-stimulating hormone response to thyrotropin-releasing hormone testing. These changes were considered to be compensatory adjustments by the pituitary-thyroid axis to competitive inhibition of 5'-monodeiodinase by the amiodarone. Routine screening of thyroid function is needed to allow early detection of hypothyroidism when these compensations fail to occur.
在连续15名儿童(平均年龄13.7岁,范围0.5至19.5岁)中,在使用强效抗心律失常药物胺碘酮(可达龙)治疗前及治疗期间对甲状腺功能进行了系统评估。已知胺碘酮通过竞争性抑制5'-单脱碘酶来影响甲状腺内环境稳定,该酶可将左旋甲状腺素(T4)转化为三碘甲状腺原氨酸(T3),并将反式T3(rT3)转化为3,3'-二碘甲状腺原氨酸(T2),同时还因其高碘含量(按重量计37%)产生直接影响。三名患者出现了甲状腺功能减退的临床和/或生化证据,其中两名患者需要用左旋甲状腺素治疗。另有一名患者持续存在高甲状腺素血症,但无甲状腺功能亢进的临床证据。甲状腺功能正常的患者血清甲状腺功能检查结果出现了特征性改变。这些改变包括血清T4、rT3、基础促甲状腺激素以及促甲状腺激素对促甲状腺激素释放激素试验的反应显著增加。这些变化被认为是垂体-甲状腺轴对胺碘酮竞争性抑制5'-单脱碘酶的代偿性调整。当这些代偿未能发生时,需要进行甲状腺功能的常规筛查以便早期发现甲状腺功能减退。